Major contribution of the multidrug transporter p-glycoprotein to reduced susceptibility of poly(ADP-ribose) polymerase-1 knock-out cells to doxorubicin action

Journal of Cellular Biochemistry

Volumn 95, Issue 5, 2005, Pages 1012-1028

  Wȩsierska Ga̧dek, Józefa ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Apoptosis; Caspases 3 7 activation; CDKs activity; Cell cycle arrest; Doxorubicin uptake; G2 accumulation; MDR1; Multidrug resistance; p53 activation; Site specific phosphorylation

Indexed keywords

ACRIDONE DERIVATIVE; C 1305; CASPASE 3; CASPASE 7; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; ETOPOSIDE; GLYCOPROTEIN P; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; TRIAZOLOACRIDONE; UNCLASSIFIED DRUG;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL CYCLE; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENCY; DRUG TRANSPORT; DRUG UPTAKE; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; FIBROBLAST; GENE TARGETING; IMMUNOBLOTTING; KNOCKOUT GENE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; APOPTOSIS; CALCIUM CHANNEL BLOCKERS; CASPASE 3; CASPASE 7; CASPASES; CELLS, CULTURED; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; DRUG THERAPY, COMBINATION; FIBROBLASTS; G2 PHASE; HUMANS; MICE; MICE, KNOCKOUT; MULTIPLE MYELOMA; P-GLYCOPROTEIN; PHOSPHORYLATION; POLY(ADP-RIBOSE) POLYMERASES; S PHASE; VERAPAMIL;

EID: 26444530671     PISSN: 07302312     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcb.20467     Document Type: Article

References (42)

1. Abbaszadegan MR, Cress AE, Futscher BW, Bellamy WT, Dalton WS. 1996. Evidence for cytoplasmic P-glycoprotein location associated with increased multidrug resistance and resistance to chemosensitizers. Cancer Res 56: 5435-5442.
2. Ame JC, Spenlehauer C, de Murcia G. 2004. The PARP superfamily. Bioessays 26:882-893.
3. Baldini N, Scotlandi K, Serra M, Shikita T, Zini N, Ognibene A, Santi S, Ferracini R, Maraldi NM. 1995. Nuclear immunolocalization of P-glycoprotein in multi-drug-resistant cell lines showing similar mechanism of doxorubicin distribution. Eur J Cell Biol 68:226-239.
4. Banerjee D, Lenz HJ, Schnieders B, Manno DJ, Ju JF, Spears CP, Hochhauser D, Danenberg K, Bertino JR. 1995. Transfections of wild-type but not mutant p53 induces early monocytic differentiation in HL-60 cells and increases their sensitivity to stress. Cell Growth Differ 6:1405-1413.
5. Calabrese CR, Almassy R, Barton S, Batey MA, et al. 2004. Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361. J Natl Cancer Inst 96:56-67.
6. Capco DG, Wan KM, Penman S. 1982. The nuclera matrix: Three dimensional architecture and protein composition. Cell 29:847-855.
7. Chatterjee S, Cheng MF, Berger RB, Berger SJ, Berger NA. 1995. Effect of inhibitors of poly(ADP-ribose) polymerase on the induction of GRP78 and subsequent development of resistance to etoposide. Cancer Res 55:868-873.
8. Chen CJ, Chin JE, Ueda K, Clark DP, Pastan I, Gottesman MM, Roninson IB. 1986. Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell 47:381-389.
9. Chin KV, Ueda K, Pastan I, Gottesman MM. 1992. Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science 255:459-462.
10. Cole SP, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AM, Deeley RG. 1992. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258:1650-1654.
11. d'Adda di Fagagna F, Hande MP, Tong WM, Lansdorp PM, Wang ZQ, Jackson SP. 1999. Functions of poly(ADP-ribose) polymerase in controlling telomere length and chromosomal stability. Nat Genet 23:76-80.
12. D'Amours D, Desnoyers S, D'Silvia I, Poirier GG. 1999. Poly(ADP-ribosyl)ation reactions in the regulations of nuclear functions. Biochem J 342:249-268.
13. Dalla-Favera R, Wong-Staal F, Gallo RC. 1982. One gene amplification in promyelocytic leukemia cell line HL-60 and primary leukaemic cells of the same patient. Nature 299:61-63.
14. Dalton WS, Durie BG, Alberts DS, Gerlach JH, Cress AE. 1986. Characterization of a new drug-resistant human myeloma cell line that expresses P-glycoprotein. Cancer Res 46:5125-5130.
15. Dalton WS, Grogan TM, Rybski JA, Scheper RJ, Richter L, Kailey J, Broxterman HJ, Pinedo HM, Salmon SE. 1989. Immunohistochemical detection and quantification of P-glycoprotein in multiple drug-resistant human myeloma cells: Association with level of drug-resistance and drug accumulation. Blood 73:747-752.
16. Delaney CA, Wang LZ, Kyle S, White AW, Calvert AH, Curtin NJ, Durkacz BW, Hostomsky Z, Newell DR. 2000. Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor lines. Clin Cancer Res 6:2860-2867.
17. Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK, Ross DD. 1998. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA 95:15665-15670.
18. Duesberg P, Stindl R, Hehlmann R. 2001. Origin of multidrug resistance in cells with and without multidrug resistance genes: Chrmosome reassortments catalyzed by aneuploidy. Proc Natl Acad Sci USA 98: 11283-11288.
19. Dunkers TR, Wedemeyer I, Baumgartner M, Fritz G, Kaina B. 2003. Resistance of p53 knockout cells to doxorubicin is related to reduced formation of DANN strand breaks rather that impaired apoptotic signaling. DNA Repair-(Amst) 2:49-60.
20. Gottesman MM. 1993. How cancer cells evade chemotherapy: Sixteenth Richard and Hinda Rosenthal Foundation Award lecture. Cancer Res 53:747-754.
21. Helin K. 1998. Regulation of cell proliferation by the E2F transcription factors. Curr Opin Genet Dev 8:28-35.
22. Juliano RL, Ling V. 1976. A surface glycoprotein modulating the drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 455:152-162.
23. Kartner N, Evernden-Porelle D, Bradly G, Ling V. 1985. Detection of P-glycoprotein in multidrug-resistant cell lines by monoclonal antibodies. Nature 316:820-823.
24. Lemke K, Poidessous V, Skladanowski A, Larsen AK. 2004. The antitumor triazoloacridone C-1305 is a topoisomerase II poison with unusual properties. Mol Pharmacol 66:1035-1042.
25. Lövborg H, Wojciechowski J, Larsson R, Wesierska-Gadek J. 2002. Action of a novel anticancer agent, CHS 828, on mouse fibroblasts: Increased sensitivity of cells lacking poly(ADP-ribose) polymerase-1. Cancer Res 62:4206-4211.
26. Miyake K, Mickley L, Litman T, Zhan Z, Robey R, Cristensen B, Brangi M, Greenberger L, Dean M, Fojo T, Bates SE. 1999. Molecular cloning of cDNA which are highly overexpressed in mitoxantrone-resistant cells: Demonstration of homology to ABC transport genes. Cancer Res 59:8-13.
27. Nurse P. 1997. Regulation of the eukaryotic cell cycle. Eur J Cancer 33:1002-1004.
28. Nurse P, Masui Y, Hartwell L. 1998. Understanding the cell cycle. Nat Med 4:1103-1106.
29. Riordan JR, Ling V. 1979. Purification of P-glycoprotein from plasma membrane vesicles of Chinsese hamster ovary cell mutants with reduced colchicines permeability. J Biol Chem 254:12701-12705.
30. Scheper RJ, Bulte JW, Brakkee JG, Quak JJ, van der School E, Balm AJ, et al. 1988. Monoclonal antibody JSB-1 detects a highly conserved epitope on the P-glycoprotein associated with multi-drug resistance. Int J Cancer 42:389-394.
31. Simbulan-Rosenthal CM, Ly DH, Rosenthal DS, Konopka G, Luo R, Wang ZQ, Schultz PG, Smulson ME. 2000. Misregulation of gene expression in primary fibroblasts lacking poly(ADP-ribose) polymerase. Proc Natl Acad Sci USA 97:11274-11279.
32. Szabo C, Dawson VL. 1998. Role of poly(ADP-ribose) synthetase in inflammation and ischaemia-reperfusion. Trends Pharmacol Sci 19:287-298.
33. Vindelov LL, Christensen IJ, Keiding N, Spang-Thomsen M, Nissen NI. 1983. Long-term storage of samples for flow cytometric DNA analysis. Cytometry 3:317-322.
34. Wang Q, Beck WT. 1998. Transcriptional suppression of multidrug resistance-associated protein (MRP) gene expression by wild-type p53. Cancer Res 58:5762-5769.
35. Wang ZQ, Auer B, Stingl L, Berghammer H, Haidacher D, Schweiger M, Wagner FF. 1995. Mice lacking ADPRT and poly(ADP-ribosyl)ation develop normally but are susceptible to skin disease. Genes Dev 9:509-520.
36. Wesierska-Gadek J., Schmid G. 2000. Overexpressed poly(ADP-ribose) polymerase delays the release of rat cells from p53-mediated G1 checkpoint. J Cell Biochem 80:85-103.
37. Wesierska-Gadek J, Wang ZQ, Schmid G. 1999. Reduced stability of regularly spliced but not alternatively spliced p53 protein in PARP-deficient mouse fibroblasts. Cancer Res 59:28-34.
38. Wesierska-Gadek J, Schloffer D, Kotala V, Horky M. 2002. Escape of p53 protein from E-6 mediated degradation of HeLa cells after cisplatin therapy. Int J Cancer 101: 128-136.
39. 2 cell cycle arrest. Cancer Res 64:4487-4497.
40. Wojciechowski J, Horky M, Gueorguieva M, Wesierska-Gadek J. 2003. Rapid onset of nucleolar disintegration preceding cell cycle arrest in roscovitine-induced apoptosis of human MCF-7 breast cancer cells. Int J Cancer 106:486-495.
41. Wolf D, Rotter V. 1985. Major deletions in the gene encoding the p53 tumor antigen cause lack of p53 expression in HL-60 cells. Proc Natl Acad Sci USA 82:790-794.
42. Wurzer G, Herceg Z, Wesierska-Gadek J. 2000. Increased resistance to anticancer therapy of mouse cells lacking the poly(ADP-ribose) polymerase attributable to upregulation of the multidrug resistance gene product P-glycoprotein. Cancer Res 60:4238-4244.